Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorSeber, Selçuk
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorBaşaran, Gül
dc.date.accessioned2023-05-06T17:23:35Z
dc.date.available2023-05-06T17:23:35Z
dc.date.issued2020
dc.identifier.isbn978-625-401-191-7
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12168
dc.description.abstractOld age should be carefully evaluated before the treatment of all kinds of diseases, not only chronologically but also in functional terms. Regardless of the stage of breast cancer, it is known that older patients benefit from standard treatments as much as younger patients to the extent that they are represented in clinical trials, but we also know that toxicity is augmented in this age group. The elderly patient group is a very heterogeneous group within itself, and it is important to separate the healthier, more fit elderly group who will benefit from standard treatments from the group that can only receive standard treatment with some rehabilitation. In addition, it is one of the most important duties of the clinician to identify patients who cannot tolerate both standard and modified treatments before initiation of the cancer treatment. Today, although there are several Comprehensive Geriatric Evaluation tools which are developed for aiding the clinician for making treatment decisions, most of the elderly patients are not properly evaluated in the busy day to day clinical practice. As an alternative,parameters such as patients daily work, social enviorment, prescirbed medicines for other comorbidities, and the potential side effects of the recommended treatment should be carefully reviewed. The validity of the treatment decisions taken at the start of the treatment should be re-evaluated at each visit and if necessary, modifications should be made to maximize benefit with the least toxicity.en_US
dc.language.isoturen_US
dc.publisherOrtadogu Reklam Tanitim & Yayinciliken_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectElderlyen_US
dc.subjectbreast canceren_US
dc.subjecttreatmenten_US
dc.subjectComprehensive Geriatric Assessmenten_US
dc.subjectPhase-Iii Trialen_US
dc.subjectOlder Patientsen_US
dc.subjectAdjuvant Chemotherapyen_US
dc.subjectTrastuzumab Emtansineen_US
dc.subjectTumor Characteristicsen_US
dc.subjectPostmenopausal Womenen_US
dc.subjectDouble-Blinden_US
dc.subjectNeoadjuvant Chemotherapyen_US
dc.subjectInternational-Societyen_US
dc.titleApproach to Breast Cancer Treatment in Elderly Patientsen_US
dc.typeboobkParten_US
dc.relation.ispartofTibbi Onkoloji - Geriatrik Onkolojien_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalıen_US
dc.authoridseber, selcuk erdogan/0000-0001-9081-2405
dc.identifier.startpage77en_US
dc.identifier.endpage87en_US
dc.institutionauthorSeber, Selçuk
dc.relation.publicationcategoryKitap Bölümü - Uluslararasıen_US
dc.authorwosidseber, selcuk erdogan/H-3327-2017
dc.identifier.wosWOS:000773800000014en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster